logo-loader

Nanobiotix study gaining significant traction

Published: 07:57 13 Nov 2015 GMT

radiotherapy2
The technology is designed to make radiotherapy much more effective.

Nanobiotix (EPA:NANO) said it has been ‘impressed by the growing dynamism’ of a pivotal clinical trial of a revolutionary new cancer treatment it is pioneering.

The phase II/III ‘Act.in.sarc’ study has expanded rapidly since launch at the end of last year as now be taking place at 29 sites in seven separate countries.

Researchers are looking at the efficacy of NBTXR3 in tackling a cancer of the skin and muscle called soft tissue sarcoma.

The nano-medicine is injected directly into the tumour and works to make traditional radiotherapy more targeted and much more effective.

Once the tumour is shrunk it can often be completely removed.

Elsa Borghi, the chief medical officer of Nanobiotix, said: “We are delighted with the growing dynamism of the study and the enthusiasm of our clinicians and other partners.

“NBTXR3 has the potential to significantly improve the efficiency of radiotherapy treatments across oncology indications, and the “Act.in.sarc” study could be the first step towards the generalization of the technology.” 

 

Oriole Resources outlines 2023 achievements and future exploration plans

Oriole Resources PLC (AIM:ORR) CEO Tim Livesey and chief financial officer Bob Smeeton join Proactive's Stephen Gunnion with details of the company's 2023 financial and operational performance. Livesey highlighted successful exploration programs in Cameroon, at the Bibemi and Mbe projects,...

10 minutes ago